CRO vs CDMO: What's the Difference? (2026 Guide)

Key Takeaways

• Different jobs in the drug lifecycle. A CRO runs the research, a CDMO makes the medicine. CROs handle preclinical studies, clinical trials, and regulatory evidence; CDMOs handle formulation, process development, and manufacturing.

• CROs do not manufacture. Their output is data and regulatory support, not drug product. CDMOs can span development through commercial supply, and some also offer clinical-stage services, which is where the confusion starts.

• Both markets are large and growing. CRO services are projected at roughly $93 billion in 2026, and the CDMO market at roughly $273 billion, both growing at close to 9% a year.

• Outsourcing is now the norm. About 40% of pharmaceutical manufacturing is outsourced and around 75% of late-stage pipelines rely on outsourced development, so most sponsors work with both types of partner.

• Choose by stage and need. Pick a CRO when you need to generate clinical evidence, a CDMO when you need to develop and produce the product, and weigh an integrated partner against best-of-breed specialists.

  

Anyone working in or selling to life sciences runs into the same alphabet soup: CRO, CDMO, CMO, CDO. Two of these, the CRO and the CDMO, get confused most often because both are outsourcing partners and both serve the same pharma and biotech sponsors. They do very different jobs. This guide explains what each one actually does, where they overlap, what the markets look like in 2026, and how a sponsor should choose.

The short answer

A CRO (Contract Research Organization) is an outsourced research and development arm. It helps sponsors design, run, monitor, and analyze preclinical studies and clinical trials, and supports the regulatory evidence needed for approval. A CRO does not manufacture the drug.

A CDMO (Contract Development and Manufacturing Organization) is an outsourced development and manufacturing partner. It takes a molecule from formulation and process development through scale-up and into commercial manufacturing. Put simply: the CRO proves the drug works and is safe; the CDMO develops and makes it.

What a CRO does

CROs focus on research and clinical development. Typical services include study design, site selection and management, patient recruitment, clinical trial monitoring, data management, biostatistics, pharmacovigilance, and regulatory submissions. Their deliverable is evidence: the clean, defensible data package a sponsor needs to move through phases and win approval.

Because their work sits in the clinical phases, CROs partner closely with sponsors during the most time-sensitive and risk-laden part of development. Clinical research services make up the largest slice of CRO revenue, around 58%, and oncology is the single biggest therapeutic area at roughly 35% of the market. For the commercial challenges CROs face winning that work, see our piece on business development challenges for small and mid-sized CROs.

What a CDMO does

CDMOs focus on development and manufacturing. Services span formulation and process development, analytical method development, scale-up, fill-finish, packaging, and commercial-scale production, often across both small molecules and biologics. The CDMO model bundles development and manufacturing under one roof so a sponsor can move from early development to final production without switching vendors.

Small molecules still lead CDMO demand, at roughly 58% of services, while small and emerging biotechs (which rarely own their own plants) are the fastest-growing client segment. The commercial dynamics of winning CDMO mandates are covered in business development challenges for CDMOs.

CRO vs CDMO at a glance

Dimension	CRO	CDMO
Core job	Research and clinical development	Development and manufacturing
Main deliverable	Clinical data and regulatory evidence	Drug product (and the process to make it)
Where in the lifecycle	Preclinical through clinical trials	Formulation through commercial supply
Manufactures drug product?	No	Yes
Typical buyers	Clinical, regulatory, R&D teams	Technical operations, supply chain, CMC teams
2026 market size (approx.)	~$93 billion	~$273 billion
Growth (CAGR, approx.)	~8.6%	~9.9%
Leading segment	Clinical research services (~58%)	Small molecules (~58%)

Where they overlap (and why the confusion)

The line blurs in two places. First, some large CDMOs also offer clinical-stage and even some clinical trial services, so a sponsor may see "clinical" on both menus. Second, both are outsourcing partners selling to the same sponsors, so buyers lump them together. The clean test remains the deliverable: if the partner's job ends in a data package, it is acting as a CRO; if it ends in a manufactured product, it is acting as a CDMO. A few organizations genuinely do both, but most specialize.

The market backdrop for 2026

Outsourcing is no longer the exception. About 40% of pharmaceutical manufacturing is now outsourced, up from 30% in 2018, and roughly 75% of late-stage pipelines rely on outsourced development. The CRO services market is forecast to grow from about $93 billion in 2026 to roughly $140 billion by 2031, while the CDMO market is projected to rise from about $273 billion in 2026 toward $581 billion by 2034. The drivers are the same on both sides: sponsors want to cut fixed costs, compress timelines, and access specialist capability, especially the small and emerging biotechs that have no in-house infrastructure.

How to choose the right partner

Choose a CRO when your need is evidence: you are planning or running studies and trials and need clinical, regulatory, and data expertise. Choose a CDMO when your need is product: you are developing a formulation, scaling a process, or securing commercial supply. Many programs need both, sequentially or in parallel.

Then decide between an integrated partner and best-of-breed specialists. An integrated or "one-stop" provider reduces handoffs and vendor management; specialists often bring deeper expertise in a specific therapeutic area, modality, or manufacturing technology. For smaller sponsors without a full commercial or operations team, a fractional business development partner can help structure the selection and the relationship.

Whichever you are, CRO or CDMO, winning these mandates depends on being visible and credible early, because sponsors research extensively before they shortlist. That is the job of structured pharmaceutical lead generation and disciplined pipeline optimization.

Frequently asked questions

What is the main difference between a CRO and a CDMO?

A CRO provides research and clinical development services and delivers data and regulatory evidence; it does not manufacture. A CDMO provides development and manufacturing services and delivers the actual drug product, from formulation through commercial supply.

Can one company be both a CRO and a CDMO?

Some organizations offer both research and manufacturing services, and certain large CDMOs also provide clinical-stage services. Most providers specialize, so always confirm scope by asking whether the deliverable is a data package or a manufactured product.

Which is bigger, the CRO or the CDMO market?

The CDMO market is larger, projected at roughly $273 billion in 2026 versus about $93 billion for CRO services, and both are growing at close to 9% a year.

Do small biotechs use CROs or CDMOs?

Usually both, at different stages. Small and emerging biotechs rely heavily on CROs to run trials and on CDMOs to develop and manufacture, since they rarely have in-house clinical operations or production facilities.

When should a sponsor engage a CRO versus a CDMO?

Engage a CRO when the priority is generating clinical evidence and managing trials. Engage a CDMO when the priority is developing the formulation and process or securing manufacturing capacity. Programs often need both in sequence.